We are live on ! Find out more
RLMD icon

Relmada Therapeutics

45 hedge funds and large institutions have $1.68M invested in Relmada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.22% less ownership

Funds ownership: 27.85% → 20.63% (-7.2%)

8% less funds holding

Funds holding: 49 → 45 (-4)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

71% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 14

86% less capital inflows, than outflows

Capital inflows: $139K | Capital outflows: $1.01M

Holders
45
Holders Change
-4
Holders Change %
-8.16%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
14
Closed
12
Calls
$20​K
Puts
–
Net Calls
+$20​K
Net Calls Change
-⁠$189​K

RLMD Hedge Fund Activity: Q1 2025 in Review

45 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2025, worth a combined $1.68M — down 62% from $4.36M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of RLMD and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 4 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $40.1K. The largest seller was Franklin Resources, cutting an estimated $417K.

  • 45 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2025, down from 49 in Q4 2024.
  • Funds reported $1.68M of Relmada Therapeutics stock for Q1 2025, down 62% quarter-over-quarter.
  • 7 funds opened new Relmada Therapeutics positions in Q1 2025 and 12 closed out, a net change of -5 holders.
  • The largest Relmada Therapeutics buyer in Q1 2025 was Goldman Sachs, an estimated $40.1K added.
  • The largest Relmada Therapeutics seller in Q1 2025 was Franklin Resources, an estimated $417K sold.

Based on aggregated 13F filings for Q1 2025.